{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:22:17Z","timestamp":1789964537321,"version":"4.0.1"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009210","name":"FDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.tube.2017.12.002","type":"journal-article","created":{"date-parts":[[2017,12,9]],"date-time":"2017-12-09T03:23:59Z","timestamp":1512789839000},"page":"17-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance"],"prefix":"10.1016","volume":"109","author":[{"given":"Vahid","family":"Lohrasbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malihe","family":"Talebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abed Zahedi","family":"Bialvaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfranco","family":"Fattorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Drancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Heidary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davood","family":"Darban-Sarokhalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tube.2017.12.002_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1871526514666140923153329","article-title":"Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials","volume":"15","author":"Jawed Ahsan","year":"2015","journal-title":"Infect Disord - Drug Targets"},{"issue":"7","key":"10.1016\/j.tube.2017.12.002_bib2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00204-016-1727-6","article-title":"Antibiotic resistance mechanisms in M. tuberculosis: an update","volume":"90","author":"Nguyen","year":"2016","journal-title":"Arch Toxicol"},{"issue":"11","key":"10.1016\/j.tube.2017.12.002_bib3","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.5588\/ijtld.15.0389","article-title":"Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015","volume":"19","author":"Zhang","year":"2015","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.tube.2017.12.002_bib4","series-title":"Global tuberculosis report 2016","author":"Organization, W.H","year":"2016"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ijantimicag.2017.02.008","article-title":"Old antibiotics for emerging multidrug-resistant\/extensively drug-resistant tuberculosis (MDR\/XDR-TB)","volume":"49","author":"Brouqui","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib6","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1183\/09031936.00079413","article-title":"Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation","volume":"43","author":"Diel","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib7","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1183\/09031936.00005613","article-title":"Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance","volume":"43","author":"Law","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijantimicag.2017.01.042","article-title":"Role of second-line injectable antituberculosis drugs in the treatment of MDR\/XDR tuberculosis","volume":"50","author":"Quenard","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"6387","key":"10.1016\/j.tube.2017.12.002_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/358591a0","article-title":"The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis","volume":"358","author":"Zhang","year":"1992","journal-title":"Nature"},{"issue":"33","key":"10.1016\/j.tube.2017.12.002_bib10","doi-asserted-by":"crossref","first-page":"27743","DOI":"10.1074\/jbc.M111.333385","article-title":"A\u00a0novel mechanism of growth phase-dependent tolerance to isoniazid in mycobacteria","volume":"287","author":"Niki","year":"2012","journal-title":"J\u00a0Biol Chem"},{"issue":"11","key":"10.1016\/j.tube.2017.12.002_bib11","first-page":"1320","article-title":"Mechanisms of drug resistance in Mycobacterium tuberculosis [State of the art series. Drug-resistant tuberculosis. Edited by CY. Chiang. Number 1 in the series]","volume":"13","author":"Zhang","year":"2009","journal-title":"Int J Tubercul Lung Dis"},{"issue":"8","key":"10.1016\/j.tube.2017.12.002_bib12","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1128\/AAC.00112-06","article-title":"Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis","volume":"50","author":"Hazb\u00f3n","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.12.002_bib13","series-title":"Genetics of drug resistance in Mycobacterium tuberculosis","author":"Zhang","year":"2000"},{"issue":"5144","key":"10.1016\/j.tube.2017.12.002_bib14","first-page":"227","article-title":"inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis","volume":"263","author":"Banerjee","year":"1994","journal-title":"Science-AAAS-Weekly Paper Edition-including Guide to Scientific Information"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib15","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1128\/AAC.01550-10","article-title":"Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis","volume":"55","author":"Campbell","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.tube.2017.12.002_bib16","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1099\/jmm.0.46718-0","article-title":"Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA","volume":"55","author":"Guo","year":"2006","journal-title":"J\u00a0Med Microbiol"},{"issue":"7","key":"10.1016\/j.tube.2017.12.002_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102383","article-title":"Detecting novel genetic variants associated with isoniazid-resistant Mycobacterium tuberculosis","volume":"9","author":"Shekar","year":"2014","journal-title":"PLos One"},{"issue":"7","key":"10.1016\/j.tube.2017.12.002_bib18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jac\/dkr173","article-title":"Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs","volume":"66","author":"Almeida Da Silva","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.tube.2017.12.002_bib19","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1128\/AAC.03169-14","article-title":"Rifampin induces hydroxyl radical formation in Mycobacterium tuberculosis","volume":"58","author":"Piccaro","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"8846","key":"10.1016\/j.tube.2017.12.002_bib20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0140-6736(93)90417-F","article-title":"Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis","volume":"341","author":"Telenti","year":"1993","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.tube.2017.12.002_bib21","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1128\/JCM.00691-14","article-title":"Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis","volume":"52","author":"Jamieson","year":"2014","journal-title":"J\u00a0Clin Microbiol"},{"issue":"9","key":"10.1016\/j.tube.2017.12.002_bib22","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1128\/AAC.33.9.1493","article-title":"Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis","volume":"33","author":"Takayama","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib23","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm0597-567","article-title":"The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol","volume":"3","author":"Telenti","year":"1997","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1128\/AAC.44.2.326-336.2000","article-title":"Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates ofMycobacterium tuberculosis","volume":"44","author":"Ramaswamy","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.tube.2017.12.002_bib25","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1128\/AAC.41.8.1677","article-title":"Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations","volume":"41","author":"Sreevatsan","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.tube.2017.12.002_bib26","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1128\/AAC.01486-07","article-title":"Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin","volume":"52","author":"Safi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.tube.2017.12.002_bib27","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1128\/AAC.41.10.2270","article-title":"Role of embB in natural and acquired resistance to ethambutol in mycobacteria","volume":"41","author":"Alcaide","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.tube.2014.12.002","article-title":"ubiA (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in Mycobacterium tuberculosis","volume":"95","author":"He","year":"2015","journal-title":"Tuberculosis"},{"issue":"4","key":"10.1016\/j.tube.2017.12.002_bib29","first-page":"1","article-title":"Mechanisms of pyrazinamide action and resistance","volume":"2","author":"Zhang","year":"2013","journal-title":"Microbiol Spectr"},{"issue":"10","key":"10.1016\/j.tube.2017.12.002_bib30","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S1473-3099(16)30190-6","article-title":"Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project","volume":"16","author":"Zignol","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.tube.2017.12.002_bib31","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int J Tubercul Lung Dis"},{"issue":"6","key":"10.1016\/j.tube.2017.12.002_bib32","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nm0696-662","article-title":"Mutations in pncA, a gene encoding pyrazinamidase\/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus","volume":"2","author":"Scorpio","year":"1996","journal-title":"Nat Med"},{"issue":"6049","key":"10.1016\/j.tube.2017.12.002_bib33","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.1208813","article-title":"Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis","volume":"333","author":"Shi","year":"2011","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.tube.2017.12.002_bib34","first-page":"e58","article-title":"Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis","volume":"3","author":"Shi","year":"2014","journal-title":"Emerg Microb Infect"},{"issue":"3","key":"10.1016\/j.tube.2017.12.002_bib35","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/AAC.41.3.540","article-title":"Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis","volume":"41","author":"Scorpio","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.tube.2017.12.002_bib36","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/AAC.44.3.528-532.2000","article-title":"pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada","volume":"44","author":"Cheng","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.tube.2017.12.002_bib37","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1128\/AAC.41.3.636","article-title":"Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms","volume":"41","author":"Sreevatsan","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0962-8479(98)80004-X","article-title":"Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis","volume":"78","author":"Hirano","year":"1998","journal-title":"Tuber Lung Dis"},{"issue":"9","key":"10.1016\/j.tube.2017.12.002_bib39","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1128\/AAC.44.9.2291-2295.2000","article-title":"Phenotypic characterization of pncAMutants of Mycobacterium tuberculosis","volume":"44","author":"Morlock","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.12.002_bib40","first-page":"dkt042","article-title":"Mycobacterium canettii is intrinsically resistant to both pyrazinamide and pyrazinoic acid","author":"Feuerriegel","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.tube.2017.12.002_bib41","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1365-2958.1993.tb01253.x","article-title":"Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot","volume":"9","author":"Finken","year":"1993","journal-title":"Mol Microbiol"},{"issue":"3","key":"10.1016\/j.tube.2017.12.002_bib42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2958.1993.tb00924.x","article-title":"The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis","volume":"10","author":"Nair","year":"1993","journal-title":"Mol Microbiol"},{"issue":"4","key":"10.1016\/j.tube.2017.12.002_bib43","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1365-2958.2006.05585.x","article-title":"Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria","volume":"63","author":"Okamoto","year":"2007","journal-title":"Mol Microbiol"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib44","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1128\/AAC.42.5.1295","article-title":"Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis","volume":"42","author":"Alangaden","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"47","key":"10.1016\/j.tube.2017.12.002_bib45","doi-asserted-by":"crossref","first-page":"20004","DOI":"10.1073\/pnas.0907925106","article-title":"Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis","volume":"106","author":"Zaunbrecher","year":"2009","journal-title":"Proc Natl Acad Sci Unit States Am"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1128\/AAC.49.2.571-577.2005","article-title":"Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis","volume":"49","author":"Maus","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.tube.2017.12.002_bib47","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1128\/AAC.49.8.3192-3197.2005","article-title":"Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis","volume":"49","author":"Maus","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"01","key":"10.1016\/j.tube.2017.12.002_bib48","first-page":"41","article-title":"DNA topoisomerases: harnessing and constraining energy to govern chromosome topology","volume":"41","author":"Schoeffler","year":"2008","journal-title":"Q\u00a0Rev Biophys"},{"issue":"8","key":"10.1016\/j.tube.2017.12.002_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012245","article-title":"Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase","volume":"5","author":"Piton","year":"2010","journal-title":"PLos One"},{"issue":"1","key":"10.1016\/j.tube.2017.12.002_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/bi052130w","article-title":"Pentapeptide repeat proteins","volume":"45","author":"Vetting","year":"2006","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.tube.2017.12.002_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/bi052130w","article-title":"The pentapeptide repeat proteins","volume":"45","author":"Vetting","year":"2006","journal-title":"Biochemistry"},{"issue":"5727","key":"10.1016\/j.tube.2017.12.002_bib52","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.1110699","article-title":"A\u00a0fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA","volume":"308","author":"Hegde","year":"2005","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib53","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1128\/JB.01205-08","article-title":"The pentapeptide repeat proteins MfpAMt and QnrB4 exhibit opposite effects on DNA gyrase catalytic reactions and on the ternary gyrase-DNA-quinolone complex","volume":"191","author":"M\u00e9rens","year":"2009","journal-title":"J\u00a0Bacteriol"},{"issue":"1","key":"10.1016\/j.tube.2017.12.002_bib54","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1128\/AAC.01228-13","article-title":"Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China","volume":"58","author":"Zhang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib55","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/jac\/dks033","article-title":"gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis","volume":"67","author":"Sirgel","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.tube.2017.12.002_bib56","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jac\/dkr566","article-title":"A\u00a0systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system","volume":"67","author":"Maruri","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.tube.2017.12.002_bib57","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijantimicag.2012.02.015","article-title":"gyrA\/B fluoroquinolone resistance allele profiles amongst Mycobacterium tuberculosis isolates from mainland China","volume":"39","author":"Long","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.tube.2017.12.002_bib58","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/1574-6968.12401","article-title":"Mechanisms of fluoroquinolone monoresistance in Mycobacterium tuberculosis","volume":"353","author":"Lu","year":"2014","journal-title":"FEMS Microbiol Lett"},{"issue":"17","key":"10.1016\/j.tube.2017.12.002_bib59","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1073\/pnas.97.17.9677","article-title":"Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis","volume":"97","author":"DeBarber","year":"2000","journal-title":"Proc Natl Acad Sci Unit States Am"},{"issue":"36","key":"10.1016\/j.tube.2017.12.002_bib60","doi-asserted-by":"crossref","first-page":"28326","DOI":"10.1074\/jbc.M003744200","article-title":"Activation of the pro-drug ethionamide is regulated in mycobacteria","volume":"275","author":"Baulard","year":"2000","journal-title":"J\u00a0Biol Chem"},{"issue":"15","key":"10.1016\/j.tube.2017.12.002_bib61","doi-asserted-by":"crossref","first-page":"12824","DOI":"10.1074\/jbc.M110751200","article-title":"The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase","volume":"277","author":"Vannelli","year":"2002","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1574-6968.2001.tb10547.x","article-title":"Characterization of the alanine racemases from two mycobacteria","volume":"196","author":"Strych","year":"2001","journal-title":"FEMS Microbiol Lett"},{"issue":"16","key":"10.1016\/j.tube.2017.12.002_bib63","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/jb.179.16.5046-5055.1997","article-title":"Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis","volume":"179","author":"Caceres","year":"1997","journal-title":"J\u00a0Bacteriol"},{"issue":"1","key":"10.1016\/j.tube.2017.12.002_bib64","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1128\/AAC.47.1.283-291.2003","article-title":"Roles of Mycobacterium smegmatis D-alanine: D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine","volume":"47","author":"Feng","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.tube.2017.12.002_bib65","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1021\/ml400349n","article-title":"Metabolomics reveal d-alanine: d-alanine ligase as the target of d-cycloserine in Mycobacterium tuberculosis","volume":"4","author":"Prosser","year":"2013","journal-title":"ACS Med Chem Lett"},{"issue":"8","key":"10.1016\/j.tube.2017.12.002_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043467","article-title":"A\u00a0point mutation in cycA partially contributes to the D-cycloserine resistance trait of Mycobacterium bovis BCG vaccine strains","volume":"7","author":"Chen","year":"2012","journal-title":"PLos One"},{"issue":"1","key":"10.1016\/j.tube.2017.12.002_bib67","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2958.2004.04120.x","article-title":"The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria","volume":"53","author":"Rengarajan","year":"2004","journal-title":"Mol Microbiol"},{"issue":"1","key":"10.1016\/j.tube.2017.12.002_bib68","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tube.2003.08.012","article-title":"Iron, mycobacteria and tuberculosis","volume":"84","author":"Ratledge","year":"2004","journal-title":"Tuberculosis"},{"issue":"32","key":"10.1016\/j.tube.2017.12.002_bib69","doi-asserted-by":"crossref","first-page":"23447","DOI":"10.1074\/jbc.M113.475798","article-title":"para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis","volume":"288","author":"Zheng","year":"2013","journal-title":"J\u00a0Biol Chem"},{"issue":"6115","key":"10.1016\/j.tube.2017.12.002_bib70","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.1228980","article-title":"Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis","volume":"339","author":"Chakraborty","year":"2013","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib71","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1128\/AAC.01197-08","article-title":"Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis","volume":"53","author":"Mathys","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.tube.2017.12.002_bib72","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1128\/AAC.01775-13","article-title":"Binding pocket\u00a0alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis","volume":"58","author":"Zhao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2017.12.002_bib73","doi-asserted-by":"crossref","first-page":"17015","DOI":"10.1038\/nrdp.2017.15","article-title":"Tuberculosis-drugs in the 2016 development pipeline. Nature reviews","volume":"3","author":"Laughon","year":"2017","journal-title":"Dis Primers"},{"issue":"4","key":"10.1016\/j.tube.2017.12.002_bib74","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S1473-3099(16)00070-0","article-title":"Tuberculosis\u2014advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers","volume":"16","author":"Wallis","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tube.2017.12.002_bib75","first-page":"60","article-title":"Tuberculosis-current advances in development of new drugs against multidrug-resistant strains","volume":"6","author":"Fernandes","year":"2017","journal-title":"EC Microbiol"},{"issue":"5707","key":"10.1016\/j.tube.2017.12.002_bib76","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A\u00a0diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.tube.2017.12.002_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2229-516X.112228","article-title":"Bedaquiline: first FDA-approved tuberculosis drug in 40 years","volume":"3","author":"Mahajan","year":"2013","journal-title":"Int J Appl Basic Med Res"},{"issue":"6","key":"10.1016\/j.tube.2017.12.002_bib78","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2217\/fmb.10.50","article-title":"TMC207: the first compound of a new class of potent anti-tuberculosis drugs","volume":"5","author":"Matteelli","year":"2010","journal-title":"Future Microbiol"},{"issue":"37","key":"10.1016\/j.tube.2017.12.002_bib79","doi-asserted-by":"crossref","first-page":"25273","DOI":"10.1074\/jbc.M803899200","article-title":"Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis","volume":"283","author":"Koul","year":"2008","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"10.1016\/j.tube.2017.12.002_bib80","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01393-08","article-title":"Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue","volume":"53","author":"Haagsma","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.tube.2017.12.002_bib81","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1128\/AAC.00181-07","article-title":"In\u00a0vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor","volume":"51","author":"Huitric","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.tube.2017.12.002_bib82","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1128\/AAC.01611-09","article-title":"Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor","volume":"54","author":"Huitric","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.tube.2017.12.002_bib83","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1128\/AAC.01039-12","article-title":"Variations of subunit \u03b5 of the Mycobacterium tuberculosis F1Fo ATP synthase and a novel model for mechanism of action of the tuberculosis drug TMC207","volume":"57","author":"Biukovi\u0107","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib84","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/AAC.00037-14","article-title":"Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis","volume":"58","author":"Hartkoorn","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.tube.2017.12.002_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102135","article-title":"Acquired resistance of Mycobacterium tuberculosis to bedaquiline","volume":"9","author":"Andries","year":"2014","journal-title":"PLos One"},{"issue":"8","key":"10.1016\/j.tube.2017.12.002_bib86","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMp1314385","article-title":"FDA approval of bedaquiline \u2014 the benefit-risk balance for drug-resistant tuberculosis","volume":"371","author":"Cox","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib87","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4103\/0253-7613.117765","article-title":"Bedaquiline: a new drug approved for treatment of multidrug-resistant tuberculosis","volume":"45","author":"Deoghare","year":"2013","journal-title":"Indian J Pharmacol"},{"issue":"8","key":"10.1016\/j.tube.2017.12.002_bib88","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib89","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1183\/13993003.01891-2015","article-title":"Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence","volume":"47","author":"Pontali","year":"2016","journal-title":"Eur Respir J"},{"issue":"23","key":"10.1016\/j.tube.2017.12.002_bib90","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"Rr-09","key":"10.1016\/j.tube.2017.12.002_bib91","first-page":"1","article-title":"Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis","volume":"62","year":"2013","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"10.1016\/j.tube.2017.12.002_bib92","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/2040622315582325","article-title":"Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?","volume":"6","author":"Field","year":"2015","journal-title":"Therap Adv Chronic Dis"},{"issue":"6789","key":"10.1016\/j.tube.2017.12.002_bib93","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A\u00a0small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"issue":"5906","key":"10.1016\/j.tube.2017.12.002_bib94","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.1164571","article-title":"PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release","volume":"322","author":"Singh","year":"2008","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib95","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1073\/pnas.0508392103","article-title":"Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis","volume":"103","author":"Manjunatha","year":"2006","journal-title":"Proceed Natnl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.tube.2017.12.002_bib96","doi-asserted-by":"crossref","first-page":"5718","DOI":"10.1128\/AAC.05500-11","article-title":"Impact of fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in\u00a0vitro susceptibility to PA-824","volume":"55","author":"Feuerriegel","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.tube.2017.12.002_bib97","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00913-17","article-title":"Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis","volume":"61","author":"Li","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.tube.2017.12.002_bib98","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in\u00a0vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.tube.2017.12.002_bib99","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/jac\/dkw044","article-title":"Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC\u2122 MGIT\u2122 960 system","volume":"71","author":"Schena","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"18","key":"10.1016\/j.tube.2017.12.002_bib100","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2174\/092986707781368496","article-title":"Novel agents in the management of Mycobacterium tuberculosis disease","volume":"14","author":"Barry","year":"2007","journal-title":"Curr Med Chem"},{"issue":"23","key":"10.1016\/j.tube.2017.12.002_bib101","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib102","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/jac\/dkm291","article-title":"Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis","volume":"60","author":"Saliu","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.tube.2017.12.002_bib103","series-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance","author":"Organization, W.H","year":"2014"},{"issue":"6","key":"10.1016\/j.tube.2017.12.002_bib104","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1183\/09031936.00125812","article-title":"Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis","volume":"41","author":"Skripconoka","year":"2013","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib105","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1183\/09031936.00176314","article-title":"Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid","volume":"45","author":"Wells","year":"2015","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.tube.2017.12.002_bib106","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1128\/JB.184.9.2420-2428.2002","article-title":"Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F420 and FO biosynthesis","volume":"184","author":"Choi","year":"2002","journal-title":"J\u00a0Bacteriol"},{"issue":"17","key":"10.1016\/j.tube.2017.12.002_bib107","doi-asserted-by":"crossref","first-page":"11832","DOI":"10.1074\/jbc.M710352200","article-title":"Molecular insights into the biosynthesis of the F420 coenzyme","volume":"283","author":"Forouhar","year":"2008","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"10.1016\/j.tube.2017.12.002_bib108","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4103\/0976-500X.136121","article-title":"Delamanid: A new armor in combating drug-resistant tuberculosis","volume":"5","author":"Xavier","year":"2014","journal-title":"J\u00a0Pharmacol Pharmacother"},{"key":"10.1016\/j.tube.2017.12.002_bib109","series-title":"Interscience conference on antimicrobial agents and chemotherapy.[poster A-960]","article-title":"Pharmacokinetics and safety of delamanid in pediatric MDR-TB patients, ages 6-17 years","author":"Hafkin","year":"2015"},{"key":"10.1016\/j.tube.2017.12.002_bib110","series-title":"The 46th union worls conference on lung health, cape Town, SA","article-title":"Long-term safety, tolerability, and pharmacokinetics of delamanid in children aged 12-17","author":"Hafkin","year":"2015"},{"issue":"3","key":"10.1016\/j.tube.2017.12.002_bib111","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1183\/13993003.00705-2016","article-title":"Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges","volume":"48","author":"Tadolini","year":"2016","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.tube.2017.12.002_bib112","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1183\/13993003.00637-2016","article-title":"First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline","volume":"48","author":"Tadolini","year":"2016","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.tube.2017.12.002_bib113","doi-asserted-by":"crossref","first-page":"949","DOI":"10.5588\/ijtld.10.0616","article-title":"Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients","volume":"15","author":"Diacon","year":"2011","journal-title":"Int J Tubercul Lung Dis"},{"issue":"6","key":"10.1016\/j.tube.2017.12.002_bib114","first-page":"939","article-title":"The Early Bactericidal Activity of Drugs in Patients with Pulmonary Tuberculosis 1, 2","volume":"121","author":"Jindani","year":"1980","journal-title":"Am Rev Respirat Dis"},{"key":"10.1016\/j.tube.2017.12.002_bib115","first-page":"dkw450","article-title":"Linezolid: a promising option in the treatment of Gram-positives","author":"Bialvaei","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.tube.2017.12.002_bib116","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1021\/jm950956y","article-title":"Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity","volume":"39","author":"Barbachyn","year":"1996","journal-title":"J\u00a0Med Chem"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib117","first-page":"181","article-title":"Linezolid Pharmacia Corp","volume":"1","author":"Barrett","year":"2000","journal-title":"Curr Opin Invest Drugs"},{"issue":"6","key":"10.1016\/j.tube.2017.12.002_bib118","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.01411-05","article-title":"Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones","volume":"50","author":"McKee","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"16","key":"10.1016\/j.tube.2017.12.002_bib119","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib120","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1128\/AAC.01189-07","article-title":"In\u00a0vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants","volume":"52","author":"Hillemann","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib121","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1128\/AAC.06227-11","article-title":"rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains","volume":"56","author":"Beckert","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.tube.2017.12.002_bib122","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijantimicag.2013.12.007","article-title":"Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China","volume":"43","author":"Zhang","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib123","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1128\/AAC.43.5.1189","article-title":"Activities of Several Novel Oxazolidinones againstMycobacterium tuberculosis in a Murine Model","volume":"43","author":"Cynamon","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.tube.2017.12.002_bib124","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2011.06330.x","article-title":"The oxazolidinones: past, present, and future","volume":"1241","author":"Shaw","year":"2011","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib125","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1128\/AAC.01179-10","article-title":"Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis","volume":"55","author":"Wallis","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.tube.2017.12.002_bib126","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1164\/rccm.200904-0611OC","article-title":"Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis","volume":"180","author":"Williams","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2017.12.002_bib127","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkr589","article-title":"SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in\u00a0vitro","author":"Reddy","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.tube.2017.12.002_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030479","article-title":"Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide","volume":"7","author":"Wallis","year":"2012","journal-title":"PLos One"},{"issue":"9","key":"10.1016\/j.tube.2017.12.002_bib129","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nm.3262","article-title":"Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis","volume":"19","author":"Pethe","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.tube.2017.12.002_bib130","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.addr.2016.04.026","article-title":"New agents for the treatment of drug-resistant Mycobacterium tuberculosis","volume":"102","author":"Hoagland","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.tube.2017.12.002_bib131","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/cid\/cir889","article-title":"Totally drug-resistant tuberculosis in India","volume":"54","author":"Udwadia","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.tube.2017.12.002_bib132","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/joim.12264","article-title":"Totally drug-resistant tuberculosis and adjunct therapies","volume":"277","author":"Parida","year":"2015","journal-title":"J\u00a0Intern Med"},{"issue":"2","key":"10.1016\/j.tube.2017.12.002_bib133","first-page":"420","article-title":"Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran","volume":"136","author":"Velayati","year":"2009","journal-title":"CGST J"},{"issue":"9","key":"10.1016\/j.tube.2017.12.002_bib134","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/cid\/civ631","article-title":"Host-directed therapies for tackling multi-drug resistant tuberculosis: learning from the Pasteur-Bechamp debates","volume":"61","author":"Zumla","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2017.12.002_bib135","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.ijmyco.2016.09.044","article-title":"Host-directed therapies for multidrug resistant tuberculosis","volume":"5","author":"Zumla","year":"2016","journal-title":"Int J Mycobacteriol"},{"issue":"4","key":"10.1016\/j.tube.2017.12.002_bib136","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri3813","article-title":"Advancing host-directed therapy for tuberculosis","volume":"15","author":"Wallis","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.tube.2017.12.002_bib137","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrd4696","article-title":"Towards host-directed therapies for tuberculosis [Comment]","volume":"14","author":"Zumla","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.tube.2017.12.002_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2017.05.005","article-title":"Host-directed therapies offer novel opportunities for the fight against tuberculosis","author":"Machelart","year":"2017","journal-title":"Drug Discov Today"},{"issue":"263","key":"10.1016\/j.tube.2017.12.002_bib139","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009885","article-title":"Metformin as adjunct antituberculosis therapy","volume":"6","author":"Singhal","year":"2014","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004917","article-title":"Neutrophil-derived MMP-8 drives AMPK-dependent matrix destruction in human pulmonary tuberculosis","volume":"11","author":"Ong","year":"2015","journal-title":"PLoS Pathog"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib141","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/infdis\/jit550","article-title":"Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation","volume":"209","author":"Parihar","year":"2013","journal-title":"J\u00a0Infect Dis"},{"issue":"5","key":"10.1016\/j.tube.2017.12.002_bib142","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.chom.2011.09.010","article-title":"Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis","volume":"10","author":"Napier","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"6","key":"10.1016\/j.tube.2017.12.002_bib143","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979217303943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979217303943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T03:57:04Z","timestamp":1660103824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979217303943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":143,"alternative-id":["S1472979217303943"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2017.12.002","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2017.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}